UHS
Universal Health Services, Inc.
UHS has a slight edge over UNH overall, supported by stronger valuation and stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
UHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
UHS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
UHS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.1x | $194 | — |
| Forward | 8.6x | $194 | — |
| Cheap | 9.7x | $231 | +19% |
| Fair | 12x | $296 | +53% |
| Expensive | 15x | $367 | +89% |
Historical ranges are pointers, not guarantees.
UHS has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
UHS Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect UHS's revenue to grow, but its profitability to weaken.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
UHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.52 | -5.6% |
| Q3 2026 | $23.86 | +13% |
| Q2 2026 | $24.50 | +29% |
| Q1 2026 | $23.95 | +35% |
| Q4 2025 | $23.10 | +37% |
| Q3 2025 | $21.03 | +40% |
| Q2 2025 | $18.97 | +39% |
| Q1 2025 | $17.80 | +51% |
| Q4 2024 | $16.82 | +64% |
UHS has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
UHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.7B | +5.3% |
| Q2 2026 | $4.6B | +8.3% |
| Q1 2026 | $4.5B | +9.6% |
| Q4 2025 | $4.5B | +9.1% |
| Q3 2025 | $4.5B | +13% |
| Q2 2025 | $4.3B | +9.6% |
| Q1 2025 | $4.1B | +6.7% |
| Q4 2024 | $4.1B | +11% |
UHS has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -2 points |
| Q2 2026 | 11% | -0.5 points |
| Q1 2026 | 11% | +0.1 points |
| Q4 2025 | 12% | 0 points |
| Q3 2025 | 12% | +1.9 points |
| Q2 2025 | 12% | +0.5 points |
| Q1 2025 | 11% | +1 points |
| Q4 2024 | 11% | +2.6 points |
UHS has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
UHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $421.6M | +178% |
| Q2 2026 | $215.7M | -24% |
| Q1 2026 | $184.5M | +52% |
| Q4 2025 | $293.5M | -29% |
| Q3 2025 | $151.8M | +78% |
| Q2 2025 | $283M | -35% |
| Q1 2025 | $121M | -36% |
| Q4 2024 | $412.5M | +68% |
UHS still generates free cash flow, though less than at its 2020 peak: $1.1B over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over UHS on cash flow, with more consistent year-over-year improvement.
UHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -765K shares |
| 1 year | -7.1% | -4.5M shares |
| 3 years | -15% | -10.5M shares |
| 5 years | -29% | -24.5M shares |
| Available history | -34% | -29.9M shares |
UHS has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $245.3M |
| Q2 2026 | $320.8M |
| Q1 2026 | $163.8M |
| Q4 2025 | $352M |
| Q3 2025 | $237.4M |
| Q2 2025 | $155.2M |
| Q1 2025 | $223.4M |
| Q4 2024 | $250.2M |
UHS spent $1.1B buying back its own shares over the past year, up 25% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
UHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
UHS's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over UHS on leverage, with a lower net debt burden relative to earnings.
UHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.4 | Neutral |
| Stochastic | 71.1 | Neutral |
UHS's weekly RSI is 60 (neutral) and its Stochastic is 71 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
UHS PE vs Healthcare Sector
| Metric | UHS | Sector median | Relative |
|---|---|---|---|
| PE | 8.1x | 26x | 69% below |
| PE % | 9 | 29 | 20 pts below |
UHS has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
UHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.7 | 5.5% above |
| 20 week MA | $173.6 | 12% above |
| 50 week MA | $183.2 | 5.8% above |
| 100 week MA | $185.2 | 4.7% above |
| 200 week MA | $174.6 | 11% above |
UHS has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
UHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143.4 | $136.9 | -4.5% |
| 2021 | $136.9 | $128.1 | -6.4% |
| 2022 | $128.1 | $140.8 | +9.9% |
| 2023 | $140.8 | $152.4 | +8.3% |
| 2024 | $152.4 | $180.5 | +18% |
| 2025 | $180.5 | $227.6 | +26% |
| 2026 YTD | $227.6 | $193.8 | -15% |
UHS has finished higher in four of the last six years. It's down 15% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over UHS on returns for 2026, with the stronger performance.